José Silvano

Check out our work on Membranous Nephropathy antigens using LMD/MS 👇 Interesting results! 🔎 Such a great honor to work with @SethiRenalPath and the @MayoClinicNeph and @mayocliniclabs team! @fervenzafernan1 @MayoClinic

Thank you for helping boost nephrology beyond imagination at the most incredible @ERAkidney Congress ever! With over 10.000 attendees and phenomenal sessions. 🇦🇹

So glad to be able to share with my colleagues the work on thirst determinants in peritoneal dialysis patients in the #ERA25. Forget salt bae 🧂🧂🧂 Check full article, published PDI journals.sagepub.com/share/CDUIXPPT…

#ERA25 HLA-incompatible desensitisation: ✅ Present options: plasmapheresis, IVIG, rituximab 🆕 Emerging therapies: obinutuzumab, ofatumumab, anti-CD38 combos 🚀 Cutting-edge in trials: Imlifidase, CAR-T, Daratumumab + Belatacept (ATTAIN study) Future is promising! 👇👇

Just go with the FLOW Last but not least... Reduced kidney function decline with semaglutide across kidney risk categories #ERA25 Dr Johannes Mann 🇩🇪

📌The 3rd presentation in Innovative Kidney Trials #ERA25 🎙️Jonathan Barratt @IgAN_JBarratt 📌ARO-C3, an investigational RNAi Therapeutic Targeting Complement C3, Reduces Proteinuria, Hematuria, and Complement Activity in IgAN 🧬ARO-C3 is an siRNA designed to achieve durable complement inhibition

🎉Late Breaking Clinical Trials II at #ERA25 is officially at capacity with over 3,000 delegates👏 💥This milestone proves one thing: nephrology is going beyond boundaries and beyond expectations. To everyone in the room: you’re part of history. To everyone online: stay tuned — the breakthroughs are just beginning. #BeyondNephrology

#ERA25 #BeyondNephrology Next on Innovative Kidney Trials session🧠 1/ 🚨 A phase I/IIa trial of regulatory T cell therapy together with donor bone marrow infusion in HLA-mismatched kidney transplantation. It’s a novel approach to donor-specific tolerance in kidney transplant using CBMKT (Combined Bone Marrow KT) + Tregs! 🎙️ Rainer Oberbauer ✖️@RainerOberbauer

6/ The impressive thing was 👉Biopsies from C3G native kidney patient who received pegetacoplan #ERA25

NEW DEFINITIONS IN CARDIO-RENAL MEDICINE Chairs: @Emor67 (SP) and @beaff26 (SP) Everything you missed on this session at the #ERA25 Always #BeyondNephrology

@VladoPerkovic announcing the 🔥 sibeprenlimab results ❤️‍🔥Plus the crowd reacting #era25

During game changers in diagnosis and treatment of complement-mediated kidney disease, Fadi Fakhuri addressing a philosophical question: 🤔Why do we need so many different drugs for complement inhibition? #ERA25

Rainer Oberbauer presented genome-wide non-HLA and HLA alloimmunity at #ERA25. ~50% of graft loss results from alloimmune reactions, such as rejections. Combining eplet scores (Eplet MM and PIRCHE) may aid in predicting de novo DSA formation. However, eplet scores are not fully reliable, suggesting non-HLA mismatches as a potential explanation. Notably, around 50% of antibody-mediated rejection (AMR) cases lack DSA, with non-HLA antibodies being a likely cause for these events. Prepared by @eroldemir83

For those who are participating in the #ERA: · Tap "Quiz & Win" in the app. · Answer 4 questions per day – you’ll earn 2 points for each correct answer. · Top scorers will be entered into a lottery to win: 🥇 1st Prize: Complimentary Congress membership for next year 🥈 2nd & 3rd Prizes: Official ERA Backpack

#ERA25 #BeyondNephrology 1/ Pro/Con Machine perfusion🤼‍♀️ Moderation by: 👤 Umberto Maggiore ✖️@UMaggiore 👤 Annemarie Weissenbacher

Presenting our moderated e-poster in the #ERA25 #beyondnephrology 📍 “INFLAMMATORY PROFILE OF INCIDENT HEMODIALYSIS PATIENTS: ROLE OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS” @Nef_HDrNegrin @SCNefrologia @ERAkidney @SENefrologia

Presentation of the ULS de Santo António (Porto) results at #ERA2025: In hereditary ATTR amyloidosis patients finerenone shows promising results in improving renal outcomes and excellent tolerability, potentially changing prognosis. A step forward in targeted cardiorrenal care.

It is rare where expectations are exceeded in kidney clinical trials. Correct answer is 52%. Only 80% of people thought it would be less.

🆕Some preliminary data on Thomas Wekerle and @RainerOberbauer Treg cells and Tolerance Induction WITHOUT myelosuppression work: 💡Belatacept monotherapy achieved in half of patients ⌛️Further results tomorrow at Innovative Kidney Trials session #ERA25 #BeyondNephrology

Presented at #ERA25: In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: nej.md/4jEVbbk @ERAkidney